Why Do I Feel Weak on Ozempic? 6 Causes and How to Fix Each One
Weakness is one of the most unsettling side effects of GLP-1 therapy — and one of the least explained. Here is exactly why it happens and what to do about it today.
Feeling weak on Ozempic, Wegovy, Mounjaro, or Zepbound is most commonly caused by inadequate calorie intake, protein deficiency, electrolyte depletion, dehydration, low blood glucose, or muscle loss. These are nutritional consequences of the appetite suppression GLP-1 medications produce — not direct toxic effects of the drugs themselves. Most cases improve significantly within days of targeted nutritional changes.
on Ozempic?
without adequate protein
Weakness on GLP-1: What Is Actually Happening
If you have started Ozempic, Wegovy, Mounjaro, or Zepbound and noticed your body feels weaker than before — muscles that tire faster, fatigue after activities that used to feel effortless, a general feeling of physical fragility — you are not imagining it and you are not alone.
Weakness is one of the most commonly reported but least clearly explained side effects of GLP-1 therapy. Most people who raise it with their prescribers are told it will pass, or that it is simply a consequence of eating less. That is partially true. But it misses the more important story about what is actually happening in the body — and what can be done about it immediately.
GLP-1 drugs suppress appetite so effectively that many users consume 600–900 calories per day without realising it. At that level of restriction, a cascade of nutritional problems develops: protein drops below the level needed to maintain muscle, electrolytes are depleted, and the body begins breaking down lean tissue for fuel. The good news is that all of these causes are identifiable and fixable.
The two causes below account for the vast majority of weakness cases on GLP-1 therapy. Causes 3–6 are real but significantly less common. Start with 1 and 2 before investigating anything else.
The 6 Causes of Weakness on GLP-1 Medications
GLP-1 medications suppress appetite so effectively that many users consume far fewer calories than they realise — often 600–900 calories per day or less for extended periods. At this level of restriction, the body has insufficient fuel to maintain energy output. Muscles cannot contract with the same force when glycogen stores are depleted. Activities that previously felt easy begin to feel disproportionately hard.
This is not a direct effect of the medication on your muscles. It is the physiological consequence of the calorie gap the medication creates. The fix is not to stop the medication — it is to ensure calorie intake stays above the minimum your body needs to function.
Track your actual calorie intake for three days. If you are consistently below 1,200 calories (women) or 1,400 calories (men), this is almost certainly contributing to your weakness. Add calorie-dense protein foods in small amounts rather than forcing large meals. See Signs You Are Not Eating Enough on GLP-1 for the specific warning signs.
Muscle tissue is constantly being broken down and rebuilt. To maintain muscle mass, your body requires a continuous supply of dietary protein — particularly the amino acid leucine, which triggers muscle protein synthesis. When protein intake drops below approximately 0.7g per pound of body weight per day, breakdown begins to outpace synthesis.
On GLP-1 therapy, where appetite suppression reduces all food intake by 30–50%, protein deficiency is extremely common. Research consistently shows that 25–40% of weight lost on GLP-1 medications without adequate protein support comes from lean muscle tissue rather than fat. Even early muscle loss produces measurable weakness.
Calculate your protein target using the GLP-1 Protein Calculator and compare it to what you are actually eating. Prioritise protein at every meal — eat it first, before vegetables and carbohydrates. GLP-1-induced satiety means you will often stop eating before finishing a full plate. Aim for a minimum of 25g per meal.
Electrolytes — particularly sodium, potassium, and magnesium — are essential for the electrical signalling that allows muscles to contract. When levels fall below normal ranges, muscle weakness is one of the first symptoms. The weakness from electrolyte imbalance tends to be more sudden in onset, can be accompanied by muscle cramping or twitching, and sometimes includes heart palpitations.
GLP-1 medications create two conditions that deplete electrolytes. First, reduced food intake means less dietary intake of potassium-rich and magnesium-rich foods. Second, gastrointestinal side effects — nausea, vomiting, and diarrhoea — cause direct electrolyte loss from the body. This is more likely during dose increases and on injection days.
Add an electrolyte supplement containing sodium, potassium, and magnesium to your daily routine. Plain water alone does not replace what is lost through GI symptoms or low food intake. Also prioritise potassium-rich foods that are tolerable even on low-appetite days: Greek yogurt, avocado, and banana. If symptoms include heart palpitations or severe muscle cramps, contact your healthcare provider promptly.
Muscle tissue is approximately 75% water by weight. A dehydration level of just 2% of body weight produces measurable reductions in strength and endurance. GLP-1 medications reduce appetite — and thirst is closely coupled with hunger. Many GLP-1 users find that when their appetite drops dramatically, they also stop drinking as much as before. They simply forget.
Dehydration-related weakness is most pronounced on injection day and in the 24–48 hours following, when nausea is often highest and the inclination to eat and drink is lowest. It is also more pronounced in users who experience vomiting, which accelerates fluid loss significantly.
Set a daily water target of at least 2–2.5 litres and track it deliberately — do not rely on thirst on GLP-1 therapy. Use a measured bottle and set reminders. Bone broth is particularly useful on high-nausea days: it provides fluid, electrolytes, and a small amount of protein in an easy-to-tolerate form. See the Energy and Hydration guide for the full daily hydration protocol.
GLP-1 medications stimulate insulin release in a glucose-dependent manner. In people with type 2 diabetes who are also taking other glucose-lowering medications — particularly sulfonylureas or insulin — this combined effect can occasionally push blood glucose too low. Classic symptoms include sudden, acute weakness, shakiness, sweating, and light-headedness.
For people using GLP-1 medications for weight loss only, hypoglycaemia is uncommon — GLP-1 medications alone do not typically cause blood glucose to drop below normal range. However, anyone who has dramatically reduced carbohydrate intake alongside GLP-1 therapy may experience low blood sugar symptoms between meals.
If you experience sudden weakness with shakiness or sweating, consume 15–20g of fast-acting carbohydrate (glucose tablets, a small glass of juice, or a few crackers) and monitor symptoms. If weakness resolves quickly, low blood glucose is likely a contributing factor. If you take diabetes medication alongside GLP-1 therapy and this happens repeatedly, contact your prescriber — your dosages may need adjustment.
If weakness has been present for several weeks or months, it may reflect actual loss of lean muscle mass. Research from clinical trials of semaglutide and tirzepatide consistently shows that 25–40% of total weight lost consists of lean mass in users who do not follow a structured protein and exercise protocol. For someone who loses 20kg on GLP-1 therapy, that could represent 5–8kg of muscle — enough to produce noticeable physical weakness and a reduced resting metabolic rate.
The key distinction from other causes is that muscle loss weakness does not resolve quickly with a single nutritional fix. Rebuilding muscle takes weeks of consistent high-protein intake combined with progressive resistance training. The earlier this is addressed, the faster the recovery.
Begin resistance training immediately — even two sessions per week of full-body compound movements produces a measurable muscle preservation signal within the first few weeks. Simultaneously, hit your daily protein target every single day. Recovery from established muscle loss requires consistency over a minimum of 6–8 weeks. The full protocol is in How to Prevent Muscle Loss on GLP-1.
The muscle loss risk on GLP-1 therapy is real — but entirely preventable with the right protein strategy. The full protocol, including targets, timing, and food sources, is in How to Prevent Muscle Loss on GLP-1 and Can You Build Muscle on Ozempic.
The Weakness Fix Protocol: Four Steps to Start Today
The most effective approach is to address all nutritional causes simultaneously rather than trying one change at a time. The causes above are often present together, and fixing one while neglecting the others produces only partial improvement.
Four Steps to Reverse GLP-1 Weakness
Calculate your protein target and compare it to what you are actually eating. If you are below 0.7g per pound of body weight per day, protein deficiency is almost certainly contributing. Use the GLP-1 Protein Calculator to find your personal target.
Add electrolytes to your daily water intake. Plain water is not enough when GI side effects are present or food intake is significantly reduced. An electrolyte sachet in 500ml of water once or twice daily replaces what reduced food intake fails to provide.
Check your total calorie intake for three days. If you are consistently below 1,200 calories, add protein-dense foods in small servings. Cottage cheese, Greek yogurt, eggs, and protein shakes deliver high protein in small volumes and work even when appetite is minimal.
Begin resistance training — even a minimal dose. Two 20-minute sessions per week of bodyweight exercises is enough to provide the muscle preservation signal that prevents further muscle loss. Weakness improves faster with this stimulus than without it.
Most people who implement these four changes simultaneously see noticeable improvement in physical strength and energy levels within 7–14 days. The timeline varies depending on which causes are most prominent and how long they have been present.
When to Contact Your Doctor
The weakness described in this article is typically nutritional in origin and responds to dietary changes. Contact your healthcare provider promptly — or call emergency services — if weakness is accompanied by any of the following:
- Chest pain, tightness, or pressure — especially radiating to the arm, jaw, or back
- Sudden facial drooping, arm weakness, or slurred speech — stroke symptoms requiring immediate emergency care
- Severe muscle cramps with heart palpitations or irregular heartbeat — possible electrolyte emergency
- Weakness that is rapidly worsening rather than stable or improving
- Unexplained severe abdominal pain alongside weakness — possible pancreatitis requiring emergency assessment
- Weakness lasting more than 4 weeks without improvement despite nutritional changes
Frequently Asked Questions
Weakness caused by inadequate calorie or protein intake typically improves within 7–14 days of targeted nutritional changes. Electrolyte-related weakness often resolves within 24–48 hours. Weakness from established muscle loss takes 4–8 weeks of consistent protein intake and resistance training to improve noticeably. If weakness persists beyond 4 weeks without improvement, contact your prescriber.
Mild weakness is common in the early weeks of GLP-1 therapy as appetite suppression reaches maximum effect. However, common does not mean it should simply be endured. In most cases it reflects a nutritional gap that can be addressed — and doing so also protects against muscle loss that would slow metabolism long-term.
Semaglutide does not appear to directly cause muscle weakness through a pharmacological mechanism acting on muscle tissue. The weakness associated with GLP-1 therapy is indirect — driven by calorie restriction, protein deficiency, and reduced physical activity that accompany the appetite suppression these medications produce. Users who maintain adequate protein intake and resistance training preserve muscle mass effectively.
Weakness in the 24–48 hours after injection reflects nausea peaking in the post-injection window and appetite suppression at its strongest, both reducing food and fluid intake further. Plan your injection day nutrition deliberately — smaller protein-dense foods, electrolyte fluids, and a protein shake if solid food is not tolerable that day.
In most cases, no. Weakness caused by nutritional gaps does not require stopping the medication — it requires addressing the gaps. Stopping GLP-1 therapy without medical guidance is associated with rapid weight regain. If you are concerned, contact your prescriber and implement the nutritional changes described in this article. Never stop a prescribed medication without first discussing it with the prescribing clinician.
Yes — and potentially to a greater degree. Tirzepatide produces more significant weight loss on average than semaglutide (approximately 20–22% vs 15% of body weight), and creates a correspondingly larger nutritional gap. Users of tirzepatide may experience more pronounced weakness if protein and calorie intake are not actively managed. The same causes and the same fixes apply to both medications.
Research & References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(4):1214–1225.
- Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength. British Journal of Sports Medicine. 2018;52(6):376–384.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. American Journal of Clinical Nutrition. 2025.
- Sawka MN, et al. American College of Sports Medicine position stand: exercise and fluid replacement. Medicine & Science in Sports & Exercise. 2007;39(2):377–390.
- Stokes T, et al. Recent perspectives regarding the role of dietary protein for the promotion of muscle hypertrophy with resistance exercise training. Nutrients. 2018;10(2):180.